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A B S T R A C T
Purpose: Phenytoin is known to be able to induce cerebellar atrophy in patients with epilepsy. It is also
known that a CYP2C9 mutation (*2 or *3) reduces phenytoin metabolism by 25–50% and can increase the
risk of phenytoin-related side effects. We examined the inﬂuence of CYP2C9 polymorphisms on total
cerebellar volume and cerebellar gray and white matter volumes in patients with epilepsy taking
phenytoin.
Methods: For the genotyping, 100 adult patients with documented epilepsy who had been taking
phenytoin for >1 year were selected. From this group, we randomly selected 19 mutant individuals (MT
group; CYP2C9*2 and *3) for a whole-brain volume measurement using MRI and 19 wild-type individuals
(group WT; CYP2C9*1) with similar clinical and demographic characteristics to those in the MT group for
comparison. Total intracranial volume measurements were used to normalize the acquired volumes,
which were separated into gray matter volume, white matter volume, and total volume.
Results: The MT group exhibited a signiﬁcant reduction in cerebellar white matter volume (p = 0.002)
but not in total cerebellar volume.
Conclusion: Our study is the ﬁrst to report evidence linking CYP2C9 polymorphism and a reduction in
cerebellar volume in epileptic users of phenytoin.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Genetic variation in the CYP2C9 gene produces altered
phenotypes that can affect metabolism. In individuals with poor
CYP2C9 metabolizer alleles, metabolism of phenytoin can be 25–
50% lower than in individuals with wild-type alleles depending on
the genetic polymorphism the patient carries and drug interac-
tions that affect the cytochrome P450 pathway.1 Several studies
have shown that the most common allelic variants are Arg144Cys
(CYP2C9*2) and Ile359Leu (CYP2C9*3), which encode enzymes with
decreased turnover rates.2 The main route by which phenytoin is
metabolized and eliminated is through hepatic oxidation by
CYP2C9 (90%) and CYP2C19 (10%).3
Cerebellar atrophy has been reported as a common ﬁnding in
patients suffering from epilepsy.4 Although the exact cause is
unknown, atrophy is often attributed to either the seizure activity
itself or antiepileptic medication,5 and phenytoin is by far the most
implicated drug.* Corresponding author at: Hospital de Clı´nicas UFPR, Rua General Carneiro, 181
38 andar, Curitiba, Parana´ CEP 80.060-900, Brazil. Tel.: +55 41 99328828;
fax: +55 41 37792083.
E-mail address: silvado@hc.ufpr.br (C. Silvado).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.12.004Since the etiology of cerebellar atrophy in phenytoin users
remains unknown, we hypothesize that CYP2C9 polymorphism
may be involved. The aim of this study was to evaluate the
relationship between poor phenytoin metabolism and cerebellar
atrophy in patients with epilepsy using this medication.
2. Methods
2.1. Subjects
Initial selection. The inclusion criteria were age 14 years and at
least one year of clearly documented use of phenytoin for epilepsy
treatment. The study was approved by the Research Ethics
Committee at the Hospital de Clı´nicas, Federal University of
Parana´. One hundred subjects were selected for genotyping. Mean
age at enrollment was 39.6  10.3 years (17–72 years) and mean age
at onset of epilepsy 13.1  12.4 years (1 month–62 years). Mean
duration of epilepsy was 26.5  11.9 years (3–48 years) and mean
length of phenytoin use was 8.3  6.9 years for all patients, with an
average maximum daily dosage of 301.5  78 mg.
2.2. CYP2C9 genotyping
Crude DNA samples were analyzed using polymerase chain
reaction-restriction fragment length polymorphism and thevier Ltd. All rights reserved.
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and CYP2C9*3 allelic variants of CYP2C9. Genotype frequencies of
the studied population were 72% for the *1/*1 genotype and 28% for
the other genotypes (*1/*2, *2/*2, *1/*3, *2/*3), showing that this
population is in Hardy–Weinberg equilibrium.6
2.3. Study groups
To compare the cerebral and cerebellar volumes of the 28
patients with at least one variant allele (mutant, or MT, group) with
the corresponding volumes of the 72 patients with wild-type CYP2C9
(wild-type, or WT, group), we randomly selected 19 individuals from
MT group. WT group we select 19 individuals that were most
matching to each one of the MT group, the selection criteria were
number of years of epilepsy and years of phenytoin use.
2.4. Imaging data
The 38 subjects were scanned on a 1.5 T GE Sigma MRI scanner
(GE Medical Systems). A 3D volume was acquired for volumetric
measurements (TR, 430 ms; TI, 12 ms; ﬂip angle, 180; matrix size,
250  250; and FOV, 25  25 cm) with continuous 1 mm-thick
slices. All image records were identiﬁed by the MRI number alone,
and observers were blinded to subjects’ genetic data when
measurements were taken.
Volumetric analyses were processed with MIPAV (version 4.3.0-
2009-08-03 from Biomedical Imaging Research Services Section,
ISL, CIT, NIH).7 All images were processed according to a semi-
automatic standard protocol.8
For measurement purposes, we considered brain volume (BV)
as the sum of the following volumes of interest (VOIs): cerebral
hemispheres, basal ganglia, inter-hemispheric ﬁssure, and pons.
Cerebellar volume (CV) and BV were calculated excluding
cerebrospinal ﬂuid (CSF). Total intracranial volume (TICV) was
considered as the sum of CV, BV, and CSF. All VOI measurements
were normalized by dividing VOI by TICV (for example, CV/
TICV*100 or BV/TICV*100) and recorded as percentages. Normal-
ized CV and BV volumes were analyzed for gray matter (GM) andTable 1
Characteristics of the MT and WT groups.
Characteristics 
Age (years) 
Female (number of individuals) 
Phenytoin maintenance dosage (mean/mg) 
Duration of phenytoin use (years) 
Epilepsy duration (years) 
Seizure frequency (monthly/median) 
Number of patients on polytherapy 
Phenobarbital 
Carbamazepine 
Lamotrigine 
Others 
Reported adverse side effects of phenytoin (number of individuals) 
Symptoms of cerebellar intoxication 
Gingival overgrowth 
EEG (number of individuals) 
Focal epileptic activity 
Nonspeciﬁc slowing 
Normal 
MRI (number of individuals) 
Mesial temporal sclerosis 
Normal 
MT: mutant group; WT: wild or control group; p value calculated with the Student’s t
a Fisher exact test.
b Chi-square test.white matter (WM) alone or for both (total). Thus, CV-GM is the
normalized cerebellar gray matter volume. We preferred to use
TICV-normalized volumes to avoid differences in volumes due to
cranial size.
2.5. Reproducibility of measurements
To determine the validity of the volumetric measurements, all
examinations were conducted twice by the same observer (intra-
rater reliability). To evaluate inter-rater reliability, 10 randomly
selected examinations were measured by another observer, who
was blinded to the previous results. The reliability of the whole
segmentation procedure, as well as volumetric analysis, was
estimated by performing the measurements in all 38 subjects. The
relative error in CV was 2.64%, with an estimated measurement
error of 0.0019. Pearson’s test indicated excellent correlation
between samples for CV (r = 0.96, p < 0.0001). Inter-observer
reproducibility was analyzed for 10 randomly selected cases.
Pearson’s correlation test also showed good results for CV (r = 0.85,
p = 0.002).
2.6. Statistical analysis
BVs and CVs for the MT and WT groups were compared by
multivariate analysis controlled for age, sex, duration of phenytoin
use, epilepsy duration, and monthly mean number of seizures. We
used the beta regression model with the Wald test. Pearson’s test
was used for inter-rater and intra-rater reliability analysis. For risk
factors and comparisons of other characteristics of the groups, we
performed a univariate analysis with Student’s t-test. Sex
distribution was compared with Fisher’s exact test.
3. Results
3.1. Group characteristics
The characteristics of both groups are summarized in Table 1.
Although the mean age in the MT group (39.3 years) was higherMT
n = 19
WT
n = 19
p value
39.3  8.4 37.9  7.9 0.20
7 10 0.33a
315  80 305  40 0.55
8.4  4.1 9.7  6.4 0.45
25.1  13.0 26.1  12.4 0.79
1.75 1 0.85
13 14 1.0b
3 4
3 4
3 2
4 4
1.0b
3 2
2 2
0.63b
10 12
4 2
5 5
0.23b
4 6
15 13
-test.
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phenytoin use and duration of epilepsy were higher in the latter, no
signiﬁcant statistical differences were observed between the
groups. The electroencephalographic ﬁndings, brain images, and
reported side effects were very similar in both groups, as can be
seen in the comparative analysis in Table 1.
3.2. Volume measurements
Multivariate analysis revealed that the normalized volume of
cerebellar white matter (CV-WM) was the only intracranial
volume that showed a signiﬁcant difference between the groups
(Table 2). Analyzing only the white matter, the adjusted cerebellar
volume was lower in the mutant CYP2C9 group (1.8% versus 2.3%;
p = 0.002). Although total CV (CV-WM + CV-GM) was lower in the
MT group than in the WT group (6.8% and 7.4%, respectively),
however this difference was not statistically signiﬁcant (p = 0.13).
4. Discussion
To date, cerebellar volume in patients with epilepsy has been
evaluated by visual inspection9 and, more recently, quantitative
imaging.4,10 Both approaches clearly show that patients with
epilepsy have smaller cerebellar volumes than normal controls. In
fact, cerebellar atrophy has an estimated prevalence of between
16.2% and 30% in these patients.5,9
In CYP2C9 mutants the maximum metabolic rate for phenytoin
can be reduced by 25–54%.11 The poor CYP2C9 metabolizer
genotype has been associated with the development of gingival
overgrowth and cutaneous reaction in patients using this drug. In
addition, some reports have suggested that use of phenytoin
causes cerebellar atrophy.4,12 This led us to hypothesize that
phenytoin users who carry the CYP2C9*2 or *3 variants, including
those who take normal doses of phenytoin, could have a higher
blood phenytoin level and be more predisposed to cerebellar
atrophy than wild-type CYP2C9 phenytoin users. In this study, we
observed that patients with epilepsy and more than one year of
phenytoin use had a reduction in CV-WM even if they carried only
one variant allele.
The pathogenesis of phenytoin-induced cerebellar atrophy is
not yet completely understood. Corroborating our ﬁndings, Liu
et al.13 emphasize that seizures or phenytoin itself could have a
regional selective effect on cerebellar volume. This selectivity may
be restricted to a histological segment such as gray or white
matter.
Comparison of both groups in our study revealed a signiﬁcant
reduction in the volume of cerebellar white matter in mutant
CYP2C9 patients. No previous work has shown such speciﬁc and
localized atrophy of cerebellar white matter in patients with poor
metabolism of phenytoin. Even though our results indicate a
localized pattern of atrophy of white matter, we believe that theTable 2
Comparison of brain volumes between the MT and WT groups.
MT (n = 19) WT (n = 19) p value
% Mean  SD % Mean  SD
Total BV 60.3  4.0 60.5  4.4 0.981
Total CV 6.8  1.2 7.4  0.8 0.130
BV-WM 30.1  2.1 31.1  2.9 0.358
CV-WM 1.8  0.3 2.3  0.4 0.002*
BV-GM 29.5  2.5 29.5  2.2 0.318
CV-GM 4.8  0.9 5.1  3.7 0.790
D: Standard deviation; CV: normalized cerebellar volume; BV: normalized brain
volume; WM: white matter; GM: gray matter; total: volume of gray matter plus
white matter. Beta regression model—Wald test. Multivariate analysis.
* p < 0.05.toxic effect of phenytoin is more diffuse (gray and white matter), as
suggested by the trend toward reduction in volume of cerebellar
gray matter in our cases and in other studies.14–18 A larger study
population would allow this hypothesis to be investigated in
greater detail.
Pathologic white matter modiﬁcations have been implicated in
both epileptogenic potential and epilepsy-related comorbidities.19
Nevertheless, there is a dearth of literature on the inﬂuence of
AEDs on brain white matter in patients with epilepsy. Adminis-
tration of phenytoin in newborn rats has been shown to lead to a
reduction in cerebellar weight and size.20 Furthermore, white
matter alterations have been reported in rats after exposure to
phenytoin, the main ﬁndings being focal axonal swellings.21 These
effects could be observed even when low doses were used and led
to cell morphological alterations and breakage of synaptic
connections. Moreover, regional effects could compromise more
than just gray matter. Indeed, volumetric studies have shown
major changes in brain white matter too.15,19 These changes can
occur locally and diffusely in both hemispheres, in the fornix,
amygdala, cingulate gyrus, thalamus, basal ganglia, temporal lobe
and cerebellum.14–18 Recently, voxel-based morphometry and
tensor diffusion studies in patients with epilepsy have shown
reductions in both white and gray matter in various parts of the
brain, including the cerebellum, compared with normal subjects.22
As in our patients, the reductions were more pronounced in white
matter. In other studies using a similar methodological procedure
to that we adopted (volume-of-interest analysis), reductions in
white matter were observed.19,23 Again, none of the studies
referred to above explore the pharmacogenetic aspects or role of
phenytoin in these white matter alterations.
The few studies that have been published about AEDs and
cerebellar volume are conﬂicting. Using multiple regression
analysis, De Marcos et al. and Luef et al.4,12 demonstrated that
duration of phenytoin treatment was a principal risk factor for the
presence of cerebellar atrophy (p = 0.001). Serum phenytoin levels
as well as duration of treatment with phenytoin could be related to
the development of cerebellar atrophy. In our study we could not
evaluate phenytoin serum levels because some patients were not
using this medication at the time. However, Luef et al. found no
correlation between serum levels of phenytoin and development of
cerebellar atrophy.12
5. Conclusion
Although several mechanisms have been implicated in the
pathogenesis of cerebellar atrophy, it seems likely that it has
multifactorial etiologies. Investigation of the pharmacogenetic
aspects of phenytoin could explain some unresolved issues
regarding the relationship between epilepsy and cerebellar
atrophy. However, conﬁrmation of the results described here by
replication in a second cohort is required.
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